Previous close | 143.95 |
Open | 144.21 |
Bid | 149.68 x 100 |
Ask | 150.24 x 100 |
Day's range | 143.96 - 151.95 |
52-week range | 141.98 - 218.88 |
Volume | |
Avg. volume | 836,019 |
Market cap | 18.963B |
Beta (5Y monthly) | 0.40 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam Pharmaceuticals (ALNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.